Full-Time

Vice President Regulatory Affairs

SAB

SAB

51-200 employees

Develops fully human polyclonal antibodies

Compensation Overview

$285k - $315k/yr

Remote in USA

Remote

Remote role with regular travel to the Sioux Falls facility; initially 1–2 weeks on-site per month.

Bachelor's

Category
Legal & Compliance (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to SAB

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific field, healthcare discipline, or regulatory discipline is required.
  • At least 15 years of regulatory affairs experience with increasing responsibility within one or more biopharmaceutical or pharmaceutical companies is required.
  • Experience interacting with the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare products Regulatory Agency is required.
  • Experience establishing Investigational New Drug applications and obtaining Biologics License Application approvals is required.
  • Experience filing and obtaining approval for New Drug Applications, Biologics License Applications, and Marketing Authorisation Applications is required.
  • Knowledge of biologic manufacturing processes, Good Manufacturing Practice principles, and related Food and Drug Administration and International Council for Harmonisation regulatory requirements is required.
  • Experience with chemistry and manufacturing controls, clinical issues and filings, technology transfer, comparability, process validation, manufacturing changes, lifecycle management, and global regulatory submissions for biologic products is required.
  • Experience leading regulatory aspects of outsourced manufacturing and third-party contract development and manufacturing organization partnerships is required.
  • Management expertise and experience leading and developing high-performance teams is required.
  • Ability to work effectively across teams, functions, and outside partners is required.
  • Familiarity with United States and international regulatory markets is required.
  • Proficiency in Microsoft Office software, including Word, Excel, PowerPoint, and Outlook, is required.
  • Ability to present information effectively in one-on-one, small-group, and laboratory meetings is required.
Responsibilities
  • Provide regulatory representation across the organization and act as liaison in interactions and communications with the Food and Drug Administration; prepare meeting summaries for regulatory archives.
  • Guide and contribute to regulatory submissions, including Investigational New Drug applications, briefing documents, orphan drug applications, breakthrough designations, Emergency Use Authorization requests, and Biologics License Applications.
  • Provide regulatory leadership for outsourced manufacturing, including technology transfer, process validation, site transfers, comparability strategies, lifecycle chemistry and manufacturing controls changes, and global submissions.
  • Assess the acceptability of quality, preclinical, and clinical documentation for regulatory submissions.
  • Develop company regulatory policies, procedures, standard operating procedures, and training for executives, upper management, and regulatory staff.
  • Develop regulatory strategy plans with deliverables and timelines and integrate business and clinical objectives with regulatory requirements.
  • Manage inspections and audits by regulatory authorities, accompany inspection teams as required, and provide follow-up input to minimize potential non-compliance findings.
  • Oversee labeling, advertising, and promotional material review for regulatory compliance.
  • Develop, implement, and manage standard operating procedures and systems for product-associated events, adverse-event reporting, product recalls, and recall communications.
  • Review change controls to determine the level of change and resulting regulatory submission requirements.
  • Ensure compliance with regulatory reporting requirements, including annual and periodic reports, and maintain annual licenses, registrations, and listings.
  • Evaluate proposed preclinical, clinical, and manufacturing changes for regulatory impact and risk and identify filing strategies.
  • Collaborate cross-functionally to align regulatory strategy, filings, and compliance activities with corporate objectives and development timelines.
  • Provide phase-appropriate strategic guidance related to current regulatory requirements and expectations for Investigational New Drug applications and Biologics License Applications.
  • Provide regulatory leadership for regulatory risk assessments, scenario planning, and decision support for development strategy, program prioritization, and corporate milestones.
  • Participate in due diligence activities as required.
  • Partner with the Senior Vice President of Regulatory Affairs and Quality Assurance to develop and implement infrastructure for Regulatory Affairs and Quality Assurance.
  • Collaborate with Quality Assurance to define, assess, and strengthen process controls across Good Practice operations and support inspection readiness.
Desired Qualifications
  • An advanced degree in a relevant field is preferred.

SAB Biotherapeutics uses the DiversitAb platform to produce fully human polyclonal antibodies in genetically engineered transchromosomic cattle, removing the need for human donors. These antibodies are designed to treat immunology disorders and infectious diseases and include programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. difficile infection. The platform can shorten development timelines, aiming to move candidates from concept to clinic in under five months, and it focuses on polyclonal antibodies rather than monoclonal ones. The company pursues regulatory approval and commercialization through collaborations with government agencies, academia, and pharmaceutical partners to address high-need diseases and biodefense applications.

Company Size

51-200

Company Stage

IPO

Headquarters

Sioux Falls, South Dakota

Founded

2014

Get referred to SAB

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 12, 2026: SAFEGUARD enrollment stayed on track for completion by end-2026.
  • July 21, 2025: Sanofi joined SAB BIO's oversubscribed $175 million private placement.
  • April 29, 2026: Emergent BioSolutions secured SAB-142 process development and manufacturing capacity.

What critics are saying

  • SAB-142 data arrives in 2H 2027; failure ends SAB BIO's only near-term value driver.
  • March 2026 dilution and July 2025 warrants pressure shares for years.
  • No approved products and $34.4 million 2025 R&D burn keep reliance on financing relentless.

What makes SAB unique

  • SAB BIO's DiversitAb platform uses transchromosomic cattle to generate fully human polyclonal antibodies.
  • SAB-142, SAB-176, and SAB-195 share one antibody-engineering platform across diseases.
  • March 2026 and April 2026 manufacturing agreements keep development and scale-up in-house.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-1%

2 year growth

-2%
Investing.com
Mar 18th, 2026
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com

SAB Biotherapeutics prices $85M stock offering at $3.85/share

Seeking Alpha
Mar 17th, 2026
SAB Biotherapeutics launches stock offering to fund SAB-142 diabetes treatment; shares fall 6.9%

SAB Biotherapeutics has launched an underwritten public offering of common stock and pre-funded warrants. The company is offering securities directly, with underwriters having the option to purchase up to 15% additional securities within 30 days. Proceeds will primarily fund development of SAB-142, the company's lead candidate for Type 1 Diabetes. The funds will also support clinical trials, manufacturing, regulatory activities and general corporate expenses. Shares fell 6.9% in post-market trading following the announcement.

Associated Press
Mar 9th, 2026
SAB BIO raises $175M, advances T1D therapy SAB-142 into registrational Phase 2b trial

SAB Biotherapeutics has reported full year 2025 financial results whilst advancing its lead candidate SAB-142 for type 1 diabetes. The company raised $175 million in an oversubscribed private placement including strategic investor Sanofi, providing operational runway through 2028. SAB has dosed multiple patients in its registrational Phase 2b SAFEGUARD study, with enrollment on track to complete by end of 2026 and topline data expected in second half of 2027. Phase 1 data released in December 2025 confirmed SAB-142's favourable safety profile, showing no serum sickness and low immunogenicity across all cohorts. The company ended 2025 with cash and securities of $143.5 million. Research and development expenses were $34.4 million, up from $30.3 million in 2024.

Money Controller
Jul 21st, 2025
SAB Biotherapeutics: $175M Private Placement Announced

SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from Sanofi and other investors. The funds will support the Phase 2b SAFEGUARD study of SAB-142 for autoimmune T1D and extend the cash runway to mid-2028. The deal includes issuing Series B nonvoting convertible preferred stock and warrants for potential additional proceeds of $284 million. The private placement is expected to close on July 22, 2025, subject to conditions.

GlobeNewswire
Jul 21st, 2025
SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Oversubscribed $175 Million Private Placement...